Erasca has backed up bullish claims about its pan-RAS drug having a best-in-class profile, publishing phase 1 data that an analyst said reveal a “home run profile.” But with a patient dying and ...

Greetings, and welcome to the Erasca Corporate Update Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce Jonathan Lim, CEO and Chairman.

SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for ...

After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib last week, Revolution Medicines is not resting on its laurels. The Bay Area biotech has spent several ...

REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The abstract will be publicly available on Thursday, May 21, 2026 on ASCO’s website, and the presentation will be made available on the Scientific Publications page of the Company’s website following ...

Islamabad: The Higher Education Commission (HEC) is preparing to introduce a blockchain-powered digital degree attestation system that will allow students to verify their academic credentials online ...

David Pogue is a six-time Emmy winner for his stories on "CBS Sunday Morning," where he's been a correspondent since 2002. Pogue hosts the CBS News podcast "Unsung Science." He's also a New York Times ...

The commission has released the combined merit list after interview along with TSP and Non-TSP category roll number lists in PDF format. Candidates can download the result PDF and search for their ...

Earlier this week, Revolution Medicines reported positive results from a global Phase III trial of its RAS‑targeting inhibitor daraxonrasib (RMC-6236) in metastatic pancreatic ductal adenocarcinoma ...

WASHINGTON, April 15 (Reuters) - U.S. import prices increased less than expected in March, though the trend still pointed to firming imported inflationary pressures as the Middle East conflict boosts ...